Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
24.5 GBX | -3.92% | -18.33% | +58.06% |
04-18 | Renalytix chief business officer to become president | AN |
04-18 | Renalytix Names Chief Business Officer as President | MT |
Sales 2024 * | 4M 5.47M | Sales 2025 * | 18M 24.6M | Capitalization | 47.11M 64.39M |
---|---|---|---|---|---|
Net income 2024 * | -35M -47.84M | Net income 2025 * | -26M -35.54M | EV / Sales 2024 * | 11.8 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.62 x |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 102 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 71.73% |
Latest transcript on Renalytix Plc
1 day | -3.92% | ||
1 week | -18.33% | ||
Current month | -26.87% | ||
1 month | -30.00% | ||
3 months | +108.51% | ||
6 months | -40.24% | ||
Current year | +58.06% |
Managers | Title | Age | Since |
---|---|---|---|
James McCullough
FOU | Founder | 56 | 18-03-14 |
James Sterling
DFI | Director of Finance/CFO | 54 | 18-03-14 |
Thomas McLain
PSD | President | 66 | 19-07-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Levangie
BRD | Director/Board Member | 73 | 21-08-29 |
Chairman | 72 | 18-03-14 | |
James McCullough
FOU | Founder | 56 | 18-03-14 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 24.5 | -3.92% | 170,170 |
24-04-25 | 25.5 | -3.77% | 43,867 |
24-04-24 | 26.5 | -3.64% | 105,921 |
24-04-23 | 27.5 | -5.17% | 248,283 |
24-04-22 | 29 | -3.33% | 4,852 |
Delayed Quote London S.E., April 26, 2024 at 11:35 am
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+58.06% | 47.11M | |
-12.91% | 19.08B | |
-46.21% | 2.65B | |
+18.15% | 1.87B | |
-3.12% | 1.61B | |
+23.78% | 1.21B | |
-10.69% | 1.02B | |
-20.89% | 905M | |
-7.14% | 716M | |
-18.10% | 682M |
- Stock Market
- Equities
- RENX Stock